Biol. Pharm. Bull. 28(6) 1120—1122 (2005)
نویسندگان
چکیده
methicillin-resistant Staphylococcus aureus (MRSA) in hospitals have become a serious clinical problem. A glycopeptide antibiotic, vancomycin, has been used for the treatment of infections due to MRSA. Enterococci, which have some a part of the normal faecal flora of humans and animals have generally emerged as important nosocomial pathogens. Acquired resistance to vancomycin and teicoplanin in enterococci is due to the replacement of the cell wall component DAla–D-Ala replaced by the depsipeptide D-Ala–D-lactate. This substitution leads to the formation of modified peptidoglycan precursors, for which glycopeptides exhibit 1000-fold lower binding affinities. In most clinical isolates of enterococci, resistance is due to acquisition for plasmids that are often transferable to other gram-positive bacteria by conjugation. Recently, MRSA strain which has vanA gene with high resistance to vancomycin (minimum inhibitory concentration (MIC) 128 mg/ml), has been reported in clinical isolates. Therefore, a new anti-MRSA antibiotic, which differs from vancomycin in its mode of action, is clinically of interest. In the course of our screening system for new anti-MRSA and anti-vancomycin resistant Enterococci (VRE) antibiotics from some phenolic compounds, we investigated the antibacterial activity of propofol (2,6-diisopropylphenol), tocopherol, eugenol, butylated hydroxyanisole (BHA), and several of their dimer compounds. Dipropofol, which is an oxidative compound of propofol, showed inhibitory activity against gram-positive bacteria. The present study deals with antibacterial activities of propofol, dipropofol and related phenols.
منابع مشابه
Biol. Pharm. Bull. 28(10) 2026—2027 (2005)
Shuso TAKEDA, Yuji ISHII, Peter I. MACKENZIE, Kiyoshi NAGATA, Yasushi YAMAZOE, Kazuta OGURI, and Hideyuki YAMADA* a Graduate School of Pharmaceutical Sciences, Kyushu University; Fukuoka 812–8582, Japan: b Department of Clinical Pharmacology, Flinders Medical Centre and Flinders University; Adelaide, SA5042, Australia: c Graduate School of Pharmaceutical Sciences, Tohoku University; Sendai 980–...
متن کاملBiol. Pharm. Bull. 28(3) 563—564 (2005)
Tomomi NOGUCHI, Chihiro SHINJI, Hisayoshi KOBAYASHI, Makoto MAKISHIMA, Hiroyuki MIYACHI, and Yuichi HASHIMOTO* Institute of Molecular & Cellular Biosciences, The University of Tokyo; 1–1–1 Yayoi, Bunkyo-ku, Tokyo 113–0032, Japan: and Department of Biochemistry, Nihon University, School of Medicine; 30–1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173–8610, Japan. Received January 13, 2005; accepted Ja...
متن کاملBiol. Pharm. Bull. 28(5) 937—939 (2005)
a Laboratory of Medicinal Pharmacognosy, Tokyo University of Pharmacy and Life Science, School of Pharmacy, 1432–1 Horinouchi, Hachioji, Tokyo 192–0392, Japan: b Functional Foods Development Division, Kaneka Corporation; Takasago, Hyogo 676–8688, Japan: c Life Science Research Laboratories, Life Science RD Center, Kaneka Corporation; Takasago, Hyogo 676–8688; Japan: d Division of Molecular Meta...
متن کاملBiol. Pharm. Bull. 28(4) 768—771 (2005)
Rat pheochromocytoma PC12 cells undergo neuronal differentiation in response to nerve growth factor. We show here that exposure of PC12 cells to Nardostachys chinensis glycoside induces the outgrowth of neurites, increases the activity of AChE, triggers cell cycle arrest in G1 and enhances the expression of growth associated protein 43 (GAP-43). Both the outgrowth of neurites and the increase i...
متن کاملBiol. Pharm. Bull. 28(2) 374—377 (2005)
cales) are known to contain structurally unique secondary metabolites, such as plastoquinones, chromanols, a cyclopentenone, and polysaccharides. These compounds show various biological activities due to their unique structure. We previously reported that the methanolic extract of the brown alga, Sargassum micracanthum (KUETZING) ENDLICHER, “Togemoku” in Japanese, showed strong antioxidant acti...
متن کامل